Výsledky vyhledávání - "Jacob L. Schillo"

Akademický článek

Understanding cancer drug resistance with Sleeping Beauty functional genomic screens: Application to MAPK inhibition in cutaneous melanoma

Autor: Eliot Y. Zhu, Jacob L. Schillo, Sarina D. Murray, Jesse D. Riordan, Adam J. Dupuy

Publikováno v: iScience, Vol 26, Iss 10, Pp 107805- (2023)

Summary: Combined BRAF and MEK inhibition is an effective treatment for BRAF-mutant cutaneous melanoma. However, most patients progress on this treatment due to drug resistance. Here, we applied the Sleeping Beauty transposon system to understand how

Externí odkaz: https://doaj.org/article/307a6faef0774c0fa828d7bf2cb30974

Zobrazit plný text záznamu

Data from Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma

Autor: Adam J. Dupuy, Christopher S. Stipp, Jesse D. Riordan, Jeremy Bobera, Sarah A. Mullen, Brooke M. Jennings, Eliot Y. Zhu, Andrew P. Voigt, Lexy S. Wadsworth, Hayley R. Vaughn, Afshin Varzavand, Jacob L. Schillo, Charlotte R. Feddersen

The use of selective BRAF inhibitors (BRAFi) has produced remarkable outcomes for patients with advanced cutaneous melanoma harboring a BRAFV600E mutation. Unfortunately, the majority of patients eventually develop drug-resistant disease. We employed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eaeb0dd15610b75d4835c5c2b200b47
https://doi.org/10.1158/0008-5472.c.6510806

Zobrazit plný text záznamu

Supplementary Data from Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma

Supplemental figures showing more detailed analysis of the genetic screen results (S1-S3), additional experiments showing biological validation of major candidate genes (S4-S7), and characterization of spontaneous Vemurafenib resistance in A375 cells

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::763c2810c62639764eae9b5898ddc732
https://doi.org/10.1158/0008-5472.22420994

Zobrazit plný text záznamu

Supplemental Tables from Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma

This file contains 4 supplemental tables.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bb40e1219583d6c2b577a68cb4a9de0
https://doi.org/10.1158/0008-5472.22420997.v1

Zobrazit plný text záznamu

Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma

Autor: Jeremy Bobera, Charlotte R. Feddersen, Sarah A. Mullen, Jesse D. Riordan, Lexy S. Wadsworth, Jacob L. Schillo, Adam J. Dupuy, Hayley R. Vaughn, Christopher S. Stipp, Brooke M. Jennings, Andrew P. Voigt, Afshin Varzavand, Eliot Y. Zhu

Publikováno v: Cancer Research. 79:5074-5087

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6f4adc244e6e093a02c0e524ce30cb6
https://doi.org/10.1158/0008-5472.can-19-0244

Zobrazit plný text záznamu

Abstract PR17: Sleeping Beauty mutagenesis reveals a Src-dependent DBL GEF family signaling mechanism driving MAPK inhibitor resistance in BRAF mutant melanoma

Autor: Charlotte R. Feddersen, Hayley R. Vaughn, Jesse D. Riordan, Eliot Y. Zhu, Andrew Voight, Afshin Varzavand, Jacob L. Schillo, Christopher S. Stipp, Adam J. Dupuy

Publikováno v: Cancer Research. 80:PR17-PR17

BRAF/MEK inhibition remains an important treatment option for patients with BRAF V600 mutant melanoma who show disease progression on immunotherapy; however, the majority of patients treated with BRAF/MEK (MAPKi) therapy develop MAPKi-resistant disea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ba289a57a6b193f933ca5c4113a43f6
https://doi.org/10.1158/1538-7445.mel2019-pr17

Zobrazit plný text záznamu

Abstract B08: Identification and characterization of Rho family GTPases as drivers of drug resistance in BRAFV600 mutant melanoma

Autor: Eliot Y. Zhu, Christopher S. Stipp, Lexy S. Wadsworth, Afshin Varzavand, Adam J. Dupuy, Hayley R. Vaughn, Charlotte R. Feddersen, Jacob L. Schillo, Andrew P. Voigt, Jesse D. Riordan

Publikováno v: Cancer Research. 80:B08-B08

The serine/threonine protein kinase BRAF is mutated in approximately 50% of cutaneous melanomas, leading to hyperactivation of the MAPK/ERK pathway. The most common mutations, BRAFV600, can be targeted by selective kinase inhibitors, such as vemurafe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26f96739d9f666291119367ed3ada86d
https://doi.org/10.1158/1538-7445.mel2019-b08

Zobrazit plný text záznamu

Abstract LB-096: A gain-of-function screen identifies drivers of drug resistance in BRAFV600E melanoma cell lines

Autor: Adam J. Dupuy, Hayley R. Vaughn, Charlotte R. Feddersen, Andrew P. Voigt, Lexy S. Wadsworth, Jacob L. Schillo, Christopher S. Stipp, Eliot Y. Zhu

Publikováno v: Cancer Research. 78:LB-096

Melanoma is the deadliest form of skin cancer, and until recently patients had few treatment options upon diagnosis. Fortunately, this lack of treatment options changed with the discovery of vemurafenib, a highly selective kinase inhibitor that speci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::14604dc389b1133fdd723dc7fac153a6
https://doi.org/10.1158/1538-7445.am2018-lb-096

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání